U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N8O5
Molecular Weight 390.354
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REGADENOSON ANHYDROUS

SMILES

CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2

InChI

InChIKey=LZPZPHGJDAGEJZ-AKAIJSEGSA-N
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H18N8O5
Molecular Weight 390.354
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
16.0 µM [Ki]
1.3 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
LEXISCAN

Cmax

ValueDoseCo-administeredAnalytePopulation
13.6 ng/mL
400 μg single, intravenous
REGADENOSON plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
11.7 ng × h/mL
400 μg single, intravenous
REGADENOSON plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 μg single, intravenous
REGADENOSON plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and radiopharmaceutical.
Route of Administration: Intravenous
In Vitro Use Guide
10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.
Substance Class Chemical
Record UNII
7AXV542LZ4
Record Status Validated (UNII)
Record Version